Crestor has been associated with a much greater risk, reports FDA
July 19, 2005 06:50

5/31/05: A pre-published article in Circulation last week reported that the cholesterol-lowering drug Crestor has been associated with a much greater frequency of reports to the U.S. Food and Drug Administration that other statin drugs (eg, Lipitor, Zocor, Pravachol). Unfortunately, the article did not offer any solutions, nor has the FDA. Jay S. Cohen M.D., a nationally recognized expert on medication side effects, has been writing and speaking about the increased risks with Crestor since the drug was first approved. Dr. Cohen believes that many of the problems with Crestor can be prevented with simple measures that the FDA must undertake to ensure patients' safety.